Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZIMMER BIOMET HOLDINGS

(ZBH)
  Report
Delayed Nyse  -  01:01 2022-11-25 pm EST
119.21 USD   +1.02%
11/23Health Care Up on Growth Optimism -- Health Care Roundup
DJ
11/23Wells Fargo Upgrades Zimmer Biomet Holdings to Equalweight from Underweight, Raises Price Target to $124 From $116
MT
11/22Zimmer Biomet Expands Persona Knee System Portfolio with FDA Clearance of Persona OsseoTi Keel Tibia for Cementless Knee Replacement
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zimmer Biomet to Present at Morgan Stanley 20th Annual Global Healthcare Conference and J.P. Morgan 13th Annual U.S All Stars Conference

08/30/2022 | 09:04am EST

WARSAW - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Executive Management Team will be presenting at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 10:30 a.m. Eastern Time and at the J.P. Morgan 13th Annual U.S.

All Stars Conference on Tuesday, September 20, 2022, at 14:00 British Summer Time (9:00 a.m. Eastern Time).

A live webcast of the presentations can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcasts will be archived for replay following the conference.

About Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

Contact:

Keri Mattox

Tel: 703-346-3127

Email: keri.mattox@zimmerbiomet.com

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
JPMORGAN CHASE & CO. 0.19% 136.74 Delayed Quote.-13.81%
MORGAN STANLEY 1.09% 90.91 Delayed Quote.-8.38%
ZIMMER BIOMET HOLDINGS 1.02% 119.21 Delayed Quote.-5.20%
All news about ZIMMER BIOMET HOLDINGS
11/23Health Care Up on Growth Optimism -- Health Care Roundup
DJ
11/23Wells Fargo Upgrades Zimmer Biomet Holdings to Equalweight from Underweight, Raises Pri..
MT
11/22Zimmer Biomet Expands Persona Knee System Portfolio with FDA Clearance of Persona Osseo..
AQ
11/21Zimmer Biomet Holdings Says FDA Cleared Persona OsseoTi Keel Tibia for Knee Replacement
MT
11/21Zimmer Biomet to Present at the 34th Annual Piper Sandler Healthcare Conference
PR
11/21Zimmer Biomet Expands Persona« Knee System Portfolio with FDA Clearance of Persona« Oss..
PR
11/21Zimmer Biomet Holdings, Inc. Expands Persona(R) Knee System Portfolio with FDA Clearanc..
CI
11/07Zimmer Biomet Announces One-Year Data from mymobility Clinical Study at 2022 AAHKS Annu..
AQ
11/05Zimmer Biomet Holdings, Inc. Announces One-Year Data from mymobility« Clinical Study at..
CI
11/03Citigroup Adjusts Zimmer Biomet Holdings' Price Target to $116 From $119, Keeps Neutral..
MT
More news
Analyst Recommendations on ZIMMER BIOMET HOLDINGS
More recommendations
Financials (USD)
Sales 2022 6 874 M - -
Net income 2022 608 M - -
Net Debt 2022 5 092 M - -
P/E ratio 2022 39,4x
Yield 2022 0,76%
Capitalization 25 017 M 25 017 M -
EV / Sales 2022 4,38x
EV / Sales 2023 4,14x
Nbr of Employees 19 500
Free-Float 66,9%
Chart ZIMMER BIOMET HOLDINGS
Duration : Period :
Zimmer Biomet Holdings Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOLDINGS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 119,21 $
Average target price 125,23 $
Spread / Average Target 5,05%
EPS Revisions
Managers and Directors
Bryan C. Hanson Chairman, President & Chief Executive Officer
Suketu P. Upadhyay Chief Financial Officer & Executive Vice President
Zeeshan Tariq Chief Information Officer & Senior Vice President
Ivan Tornos Chief Operating Officer
Angela Main Chief Compliance Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
ZIMMER BIOMET HOLDINGS-5.20%25 017
ABBOTT LABORATORIES-24.67%186 493
MEDTRONIC PLC-23.62%105 241
BECTON, DICKINSON AND COMPANY-3.43%67 460
DEXCOM, INC.-16.57%43 261
HOYA CORPORATION-14.06%37 644